New study aims to find best dose of immune therapy for nerve disorder

NCT ID NCT06752356

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 24 times

Summary

This study tests two different doses of a medicine called KIg10 (a type of immune globulin given through a vein) to see which works better as a long-term treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 161 participants will receive either a higher or lower dose for 24 weeks. The goal is to measure improvement in disability scores. This is a maintenance therapy, not a cure, so patients will need ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Neurology Epilepsy and Sleep Center/ANESC Research

    RECRUITING

    El Paso, Texas, 79912, United States

    Contact

  • USF Health - Morsani Center for Advanced Healthcare

    RECRUITING

    Tampa, Florida, 33613, United States

    Contact

Conditions

Explore the condition pages connected to this study.